- Agilent and Incyte have entered into a collaboration.
- The collaboration focuses on the development of Companion Diagnostics (CDx) in the fields of hematology and oncology.
- This partnership aims to advance personalized healthcare solutions.
Agilent, a laboratory technologies company has announced a collaboration with Incyte, a renowned biopharmaceutical company. The partnership aims to develop Companion Diagnostics (CDx) in the fields of hematology and oncology.
The collaboration between Agilent and Incyte marks a significant step forward in the development of personalised healthcare solutions. By focusing on CDx, the companies aim to ensure that the right patient receives the right treatment at the right time.
“Leveraging the power of companion diagnostics, we are strategically transforming the treatment paradigm for a broad spectrum of cancers,” said Paul Beresford, vice president and general manager of Agilent’s Companion Diagnostics Division, in the press release. “By working together, Agilent and Incyte hope to expedite the development of innovative precision medicine products, potentially paving the way for enhanced patient health outcomes.”
“Agilent’s expertise in the development of companion diagnostics is impressive, as is their regulatory and commercialisation record,” added Jeff Jackson, group vice president of Translational Medicine at Incyte, in the press release. “We are excited about the collaboration and look forward to working together to innovate in support of patients.”
Overview of outsourcing trends 
